Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights
12. Mai 2023 18:32 ET
|
Blue Water Biotech, Inc.
CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for...
Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights
09. März 2023 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December...
Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate
06. Dezember 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”) a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022
01. Dezember 2022 08:30 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine...
Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program
10. November 2022 08:47 ET
|
Blue Water Vaccines Inc.
Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for protection against non-invasive pneumococcal pneumonia in...
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022
21. September 2022 08:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
Global Pediatric Antibiotics Market to Surpass US$ 7,759.3 Million by 2030, Says Coherent Market Insights (CMI)
06. September 2022 09:15 ET
|
CMI
Seattle, Sept. 06, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global pediatric antibiotics market is estimated to be valued at US$ 6,478.9 million in 2022 and is expected to...
Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
22. August 2022 14:00 ET
|
Blue Water Vaccines Inc.
CINCINNATI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
17. September 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01. August 2019 16:20 ET
|
Otonomy, Inc.
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, Aug. 01,...